Articles by Yasin Bhanji, MD
The panel concludes with a discussion on the early use of PARP inhibitors in patients with DNA repair mutations like BRCA1/2.
The panel delves into how de novo metastases signal more aggressive prostate cancer biology.
The panel weighs the role of next-generation sequencing and emphasizes how SPOP, TP53, and RB1 guide treatment decisions.
The panel considers the evolving management of oligometastatic prostate cancer, highlighting the role of MDT.
The panel reviews treatment options for newly diagnosed mHSPC, comparing data from key doublet trials.
The panel explores scenarios where PSMA PET may not be needed, as well as limitations of conventional imaging in trials.
The panel discusses the evolving role of PSMA PET scans, imaging intervals, and distinguishing HSPC from CRPC.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.